MedTrace Logo

MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2015-03-03

No results posted yet for this study

Summary

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Conditions

  • Lower Urinary Tract Symptoms
  • Benign Prostatic Hyperplasia

Interventions

DRUG

MCS-2 15 mg/day

One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.

DRUG

MCS-2 30 mg/day

Two MCS-2 soft-gel capsules, oral daily for 12 weeks.

DRUG

Placebo

Two matching placebo soft-gel capsules, oral daily for 12 weeks.

Sponsors & Collaborators

  • Health Ever Bio-Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Allan J Pantuck, MD, MS, FACS · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002417 on ClinicalTrials.gov